Bosun Asset Management LLC Makes New Investment in Xeris Biopharma Holdings, Inc. $XERS

Key Points

• Bosun Asset Management LLC has acquired 85,111 shares of Xeris Biopharma Holdings, valued at approximately $467,000, marking a new position for the firm.
• Several analysts have upgraded Xeris Biopharma's rating to "strong-buy," with a consensus target price of $7.08.
• Insiders sold a total of 192,232 shares of Xeris Biopharma stock in the last three months, indicating a decrease in their holdings.

Bosun Asset Management LLC bought a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 85,111 shares of the company's stock, valued at approximately $467,000. Bosun Asset Management LLC owned 0.05% of Xeris Biopharma at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Wells Fargo & Company MN boosted its stake in shares of Xeris Biopharma by 38.7% in the fourth quarter. Wells Fargo & Company MN now owns 79,036 shares of the company's stock valued at $268,000 after buying an additional 22,050 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Xeris Biopharma during the 4th quarter worth approximately $45,000. MetLife Investment Management LLC increased its stake in Xeris Biopharma by 47.7% in the fourth quarter. MetLife Investment Management LLC now owns 87,432 shares of the company's stock valued at $296,000 after acquiring an additional 28,224 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Xeris Biopharma by 5.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 170,482 shares of the company's stock valued at $578,000 after acquiring an additional 9,506 shares during the last quarter. Finally, Aquatic Capital Management LLC bought a new position in Xeris Biopharma in the fourth quarter valued at approximately $50,000. Institutional investors own 42.75% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on XERS shares. Wall Street Zen cut shares of Xeris Biopharma from a "strong-buy" rating to a "buy" rating in a research note on Friday. Leerink Partners raised their target price on shares of Xeris Biopharma from $7.00 to $9.00 and gave the company an "outperform" rating in a research report on Tuesday, August 19th. Finally, HC Wainwright initiated coverage on shares of Xeris Biopharma in a report on Tuesday, August 12th. They set a "buy" rating and a $10.00 target price on the stock. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $7.08.

Xeris Biopharma Price Performance

Shares of XERS stock traded down $0.08 during trading hours on Monday, reaching $7.77. The company had a trading volume of 1,268,293 shares, compared to its average volume of 2,524,251. Xeris Biopharma Holdings, Inc. has a 12 month low of $2.51 and a 12 month high of $8.03. The business has a fifty day simple moving average of $6.19 and a 200-day simple moving average of $5.15. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -37.00 and a beta of 0.12.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.02. The business had revenue of $67.71 million during the quarter, compared to the consensus estimate of $64.58 million. On average, equities research analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Insider Activity at Xeris Biopharma

In other news, Director Dawn Halkuff sold 42,500 shares of the company's stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $7.28, for a total value of $309,400.00. Following the completion of the transaction, the director directly owned 115,000 shares in the company, valued at approximately $837,200. This represents a 26.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kevin Mcculloch bought 25,000 shares of the company's stock in a transaction dated Friday, June 13th. The shares were purchased at an average price of $4.38 per share, with a total value of $109,500.00. Following the completion of the acquisition, the insider owned 1,708,585 shares of the company's stock, valued at $7,483,602.30. This trade represents a 1.48% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 192,232 shares of company stock worth $1,430,777. Corporate insiders own 4.56% of the company's stock.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.